Literature DB >> 1947892

20 years' experience with ketoprofen.

E M Veys1.   

Abstract

Ketoprofen has emerged as a potent nonsteroidal anti-inflammatory drug. Its efficacy in the treatment of conditions such as rheumatoid arthritis and osteoarthritis has been demonstrated throughout nearly 20 years of clinical use. It has also been shown to be an effective analgesic. In comparative studies, ketoprofen appears to be at least as effective as other anti-inflammatory and analgesic agents. Because of its short half-life (approximately 1.5 hours) no dosage adjustment appears to be necessary in elderly patients unless there is concomitant renal insufficiency. Although rapidly eliminated from plasma, elimination from synovial fluid is delayed, so therapeutic concentrations can be maintained in affected joints without necessitating frequent administration. The side effects of ketoprofen are similar to those of all NSAIDs, gastrointestinal disturbances being the most frequent. Evidence for the adverse effects of NSAIDs on cartilage is still limited. Drug interactions are similar to those of all NSAIDs, antacids, methotrexate and probenecid being particularly important. Ketoprofen is available in a wide range of formulations, each designed to provide appropriate therapy in specific clinical situations: oral capsules for short term therapy; sustained release forms for chronic therapy and once-daily administration; suppositories to avoid possible gastrointestinal disturbances in susceptible patients; intramuscular preparations for rapid action; and a gel formulation for topical treatment. In the future, research should determine whether ketoprofen and other NSAIDs have any disease-modifying effects on inflammatory conditions in addition to providing symptomatic relief.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1947892

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  19 in total

1.  Comparison of tissue concentrations after intramuscular and topical administration of ketoprofen.

Authors:  I Tegeder; J Lötsch; M Kinzig-Schippers; F Sörgel; G R Kelm; S T Meller; G Geisslinger
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

2.  Effects of the noncompetitive N-methyl-d-aspartate receptor antagonists ketamine and MK-801 on pain-stimulated and pain-depressed behaviour in rats.

Authors:  T M Hillhouse; S S Negus
Journal:  Eur J Pain       Date:  2016-02-23       Impact factor: 3.931

Review 3.  Preclinical and clinical development of dexketoprofen.

Authors:  D Mauleón; R Artigas; M L García; G Carganico
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of dexketoprofen.

Authors:  M J Barbanoj; R M Antonijoan; I Gich
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Bioerodible system for sequential release of multiple drugs.

Authors:  Sharath C Sundararaj; Mark V Thomas; Thomas D Dziubla; David A Puleo
Journal:  Acta Biomater       Date:  2013-10-01       Impact factor: 8.947

6.  Ketoprofen absorption by muscle and tendon after topical or oral administration in patients undergoing anterior cruciate ligament reconstruction.

Authors:  Ichiro Sekiya; Toshiyuki Morito; Kenji Hara; Junya Yamazaki; Young-Jin Ju; Kazuyoshi Yagishita; Tomoyuki Mochizuki; Kunikazu Tsuji; Takeshi Muneta
Journal:  AAPS PharmSciTech       Date:  2010-01-20       Impact factor: 3.246

7.  Protective effects of WEB 2086 (PAF antagonist) and ketoprofen (NSAID) on PAF-induced changes in the morphological ultrastructure of blood platelets in calves.

Authors:  M B da Silva; C Dessy; J Coghe; J L David; P Lekeux
Journal:  Vet Res Commun       Date:  1998-06       Impact factor: 2.459

8.  Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis.

Authors:  E Martín-Mola; J Gijón-Baños; J J Ansoleaga
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

9.  Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial.

Authors:  Matthias Rother; Bernard J Lavins; Werner Kneer; Klaus Lehnhardt; Egbert J Seidel; Stefan Mazgareanu
Journal:  Ann Rheum Dis       Date:  2007-03-15       Impact factor: 19.103

10.  Efficacy of epicutaneous Diractin (ketoprofen in Transfersome gel) for the treatment of pain related to eccentric muscle contractions.

Authors:  Matthias Rother; Egbert J Seidel; Priscilla M Clarkson; Stefan Mazgareanu; Ulrich Vierl; Ilka Rother
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.